longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Inhibikase Therapeutics

IKT

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI
  • Biotech Stocks At 52-Week Highs - ATTO, HALO, IKT, TVTX, ATRC

    rttnews·Sep 4 at 09:20 AM
    ATTO-5.62%TVTX-1.85%
  • Inhibikase Therapeutics replaces auditor CohnReznick with Deloitte

    PUBT·Aug 26 at 08:11 PM
    IKT+1.73%
  • Biotech Stocks At 52-Week Highs - VOGX, PHVS, SOLV, IKT, HTFL

    rttnews·Aug 25 at 08:06 AM
    HTFL-0.16%VOGX-6.27%
  • Inhibikase Therapeutics Faces Rising BIOSECURE, China Supply Chain and Trial Risks That Could Disrupt Growth

    Tip Ranks·Aug 13 at 06:01 AM
    IKT+1.73%
  • Inhibikase rugi bersih Q2 FY26 melebar jadi USD 19,6 juta; belanja R&D melonjak 153,9% jadi USD 13,4 juta

    PUBT·Aug 11 at 08:12 PM
    IKT+1.73%
  • Inhibikase swaps 18,030,000 shares for RA Capital pre-funded warrant in unregistered offering

    PUBT·Jul 29 at 08:18 PM
    IKT+1.73%
  • Biotech Stocks At 52-Week Highs- IKT, HALO, JAZZ, CORT, LQDA

    rttnews·Jul 27 at 10:33 AM
    HALO-1.04%IKT+1.73%
  • Inhibikase wins FDA orphan drug designation for IKT-001 in PAH

    PUBT·Jul 23 at 12:07 PM
    IKT+1.73%
  • RA Capital Management files initial beneficial ownership statement in Inhibikase Therapeutics

    PUBT·Jul 17 at 09:55 PM
    IKT+1.73%
  • Inhibikase raises $50M to fund PAH program

    Tip Ranks·Jul 15 at 08:05 AM
    IKT+1.73%